Targeted small-molecule inhibitors of protein kinase B as anticancer agents

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 1, 2009, Pages 32-50

  Collins, Ian ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Akt; Anticancer agents; Inhibitors; Protein kinase B; Structure based design

Indexed keywords

4 (PIPERIDIN 1 YL)PYRROLO[2,3 BETA]PYRIMIDINE INHIBITOR; 4 PHENYLPYRAZOLE 6 PHENYLPURINE INHIBITOR; 5 ISOQUINOLINESULFONAMIDE DERIVATIVE; 7 AZAINDOLE; A 423795; A 443654; A 674563; BENZOQUINONE DERIVATIVE; CCT 0077933; CCT 077373; FRENOLICIN B; GSK 690693; ISOQINOLINE INHIBITOR; LACTOQUINOMYCIN; MILTEFOSINE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; NATURAL PRODUCT; NL 71 101; OXINDOLE INHIBITOR; PERIFOSINE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PX 316; PYRAZINOPYRIDINE DERIVATIVE; PYRIDOPYRIMIDINE DERIVATIVE; PYRROLO[2,3 DELTA]PYRIMIDINE INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ORGANIC COMPOUND; PROTEIN KINASE INHIBITOR;

AMINO ACID SUBSTITUTION; BREAST CANCER; CANCER THERAPY; CLINICAL TRIAL; COLON CANCER; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SCREENING; DRUG SENSITIVITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GLIOBLASTOMA; HUMAN; NEOPLASM; NONHUMAN; PANCREAS TUMOR; PH; PHARMACODYNAMICS; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT; CHEMISTRY; DRUG ANTAGONISM;

ANTINEOPLASTIC AGENTS; HUMANS; ORGANIC CHEMICALS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 61749102616     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009787047734     Document Type: Review

References (115)

1. Barnett, S.F.; Bilodeau, M.T.; Lindsley, C.W. The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation. Curr. Top Med. Chem., 2005, 5, 109.
2. Lindsley, C.W.; Barnett, S.F.; Yaroschak, M.; Bilodeau, M.T.; Layton, M.E. Recent progress in the development of ATPcompetitive and allosteric Akt kinase inhibitors. Curr. Top. Med. Chem., 2007, 7, 1349.
3. Heerding, D.A.; Safonov, I.G.; Verma, S.K. Small molecule inhibitors of AKT/PKB kinase as a strategy for treating cancer. Ann. Reports Med. Chem., 2007, 42, 365.
4. Li, Q. Recent progress in the discovery of Akt inhibitors as anticancer agents. Expert Opin. Ther. Patents, 2007, 17, 1077.
5. Hennessy, B.T.; Smith, D.L.; Prahlad, T.R.; Lu, Y.; Mills, G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature Rev. Drug Discov., 2005, 4, 988.
6. Cheng, J.Q.; Lindsley, C.W.; Cheng, G.Z.; Yang, H.; Nicosia, S.V. The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene, 2005, 24, 7482.
7. Tokunaga, E.; Kimura, Y.; Oki, E.; Ueda, N.; Futatsugi, M.; Mashino, K.; Yamamoto, M.; Ikebe, M.; Kakeji, Y.; Baba, H.; Maehara, Y. Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormonetreated patients. Int. J. Cancer, 2006, 118, 284.
8. Bader, A.G.; Khang, S.; Zhao, L.; Vogt, P.K. Oncogenic PI3K deregulates transcription and translation. Nat. Rev. Cancer, 2005, 5, 921.
9. Cully, M.; You, H.; Levine, A.J.; Mak, T.W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer, 2006, 6, 184.
10. Leslie, N.R.; Downes, C.P. PTEN function: how normal cells control it and tumour cells lose it. Biochem. J., 2004, 382, 1.
11. Testa, J.R.; Bellacosa, A. AKT plays a central role in tumorigenesis. Proc. Natl. Acad. Sci. USA, 2001, 98, 10983.
12. Carpten, J.D.; Faber, A.L.; Horn, C.; Donoho, G.P.; Briggs, S.L.; Robbins, C.M.; Hostetter, G.; Boguslawski, S.; Moses, T.Y.; Savage, S.; Uhlik, M.; Lin, A.; Du, J.; Qian, Y.; Zeckner, D.J.; Tucker-Kellog, G.; Touchman, J.; Patel, K.; Mousses, S.; Bittner, M.; Schevitz, R.; Lai, M.T.; Blanchard, K.L.; Thomas, J.E. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature, 2007, 448, 439.
13. Cappuzzo, F.; Magrini, E; Ceresoli, G.L.; Bartolini, S.; Rossi, E.; Ludovini, V.; Gregorc, V.; Ligorio, C.; Cancellieri, A.; Damiani, S.; Spreafico, A.; Paties, C.T.; Lombardo, L.; Calandri, C.; Bellezza, G.; Tonato, M.; Crino, L. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J. Natl. Cancer Inst., 2004, 96, 1133.
14. Cappuzzo, F.; Hirsch, F.R.; Rossi, E.; Bartolini, S.; Ceresoli, G.L.; Bemis, L.; Haney, J.; Witta, S.; Danenberg, K.; Domenichini, I.; Ludovini, V.; Magrini, E.; Gregorc, V.; Doglioni, C.; Sidoni, A.; Tonato, M.; Franklin, W.A.; Crino, L.; Bunn, P.A. Jr; Varella-Garcia, M. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 2005, 97, 643.
15. Haas-Kogan, D.A.; Prados, M.D.; Tihan, T.; Eberhard, D.A.; Jelluma, N.; Arvold, N.D.; Baumber, R.; Lamborn, K.R.; Kapadia, A.; Malec, M.; Berger, M.S.; Stokoe, D. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl. Cancer. Inst., 2005, 97, 880.
16. Fujita, T.; Doihara, H.; Kawasaki, K.; Takabatake, D.; Takahashi, H.; Washio, K.; Tsukuda, K.; Ogasawara, Y.; Shimizu, N. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br. J. Cancer, 2006, 94, 247.
17. Fan, Q.W.; Knight, Z.A.; Goldenberg, D.D.; Yu, W.; Mostov, K.E.; Stokoe, D.; Shokat, K.M.; Weiss, W.A. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell, 2006, 9, 341.
18. Raynaud, F.I.; Eccles, S.; Clarke, P.A.; Hayes, A.; Nutley, B.; Alix, S.; Henley, A.; Di-Stefano, F.; Ahmad, Z.; Guillard, S.; Bjerke, L.M.; Kelland, L.; Valenti, M.; Patterson, L.; Gowan, S.; de Haven Brandon, A.; Hayakawa, M.; Kaizawa, H.; Koizumi, T.; Ohishi, T.; Patel, S.; Saghir, N.; Parker, P.; Waterfield, M.; Workman, P. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res., 2007, 67, 5840.
19. Simpson, D.; Curran, M.P. Temsirolimus: in advanced renal cell carcinoma. Drugs, 2008, 68, 631.
20. Luo, Y.; Shoemaker, A.R.; Liu, X.; Woods, K.W.; Thomas, S.A.; de Jong, R.; Kan, E.H.; Li, T.; Stoll, V.S.; Powlas, J.A.; Oleksijew, A.; Mitten, M.J.; Shi, Y.; Guan, R.; McGonigal, T.P.; Klinghofer, V.; Johnson, E.F.; Leverson, J.D.; Bouska, J.J.; Mamo, M.; Smith, R.A.; Gramling-Evans, E.E.; Zinker, B.A.; Mika, A.K.; Nguyen, P.T.; Oltersdorf, T.; Rosenberg, S.H.; Li, Q.; Giranda, V.L. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol. Cancer Ther., 2005, 4, 977.
21. Rhodes, N.; Heerding, D.A.; Duckett, D.R.; Eberwein, D.J.; Knick, V.B.; Lansing, T.J.; McConnell, R.T.; Gilmer, T.M.; Zhang, S.; Robell, K.; Kahana, J.A.; Geske, R.S.; Kleymenova, E.V.; Choudry, A.E.; Lai, Z.; Leber, J.D.; Minthorn, E.A.; Strum, S.L.; Wood, E.R.; Huang, P.S.; Copeland, R.A.; Kumar, R. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res., 2008, 68, 2366.
22. Bilodeau, M.T.; Balitza, A.E.; Hoffman, J.M.; Manley, P.J.; Barnett. S.F.; Defeo-Jones, D.; Haskell. K.; Jones, R.E.; Leander, K.; Robinson, R.G.; Smith, A.M.; Huber, H.E.; Hartman, G.D. Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model. Bioorg. Med. Chem. Lett., 2008, 18, 3178.
23. Fayard, E.; Tinignac, L.A.; Baudry, A.; Hemmings, B.A. Protein kinase B/ Akt at a glance. J. Cell Sci., 2005, 118, 5675.
24. Breitenlechner, C.; Gassel, M.; Engh, R.; Bossemeyer, D. Structural insights into AGC kinase inhibition. Oncol. Res., 2004, 14, 267.
25. Traxler, P.; Furet, P.; Mett, H.; Buchdunger, E.; Meyer, T.; Lydon, N. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. J. Med. Chem., 1996, 39, 2285.
26. Sarbassov, D.D.; Guertin, D.A.; Ali, S.M.; Sabatini, D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 2005, 307, 1098.
27. Milburn, C.C.; Deak, M.; Kelly, S.M.; Price, N.C.; Alessi, D.R.; an Aalten, D.M.F. Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change. Biochem. J., 2003, 375, 531.
28. Yang, J.; Cron, P.; Good, V.M.; Thompson, V.; Hemmings, B.A.; Barford, D. Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat. Struct. Biol., 2002, 9, 940.
29. Thomas, C.C.; Deak, M.; Alessi, D.R.; Van Aalten, D.M.F. Highresolution structure of the pleckstrin homology domain of protein kinase B/Akt bound to phosphatidylinositol (3,4,5)-trisphosphate. Curr. Biol., 2002, 12, 1256.
30. Kumar, C.C.; Madison, V. AKT crystal structure and AKT-specific inhibitors. Oncogene, 2005, 24, 7493.
31. Gaßel M.; Breitenleichner, C.B.; Ruger, P.; Jucknischke, U.; Schneider, T.; Huber, R.; Bossemeyer, D.; Engh, R.A. Mutants of protein kinase A that mimic the ATP-binding site of protein kinase B (AKT). J. Mol. Biol., 2003, 329, 1021.
32. Breitenlechner, C.B.; Wegge, T.; Berillon, L.; Graul, K.; Marzenell, K.; Friebe, W.; Thomas, U.; Schumacher, R.; Huber, R.; Engh, R.A.; Masjost, B. Structure-based optimization of novel azepane derivatives as PKB inhibitors. J. Med. Chem., 2004, 47, 1375.
33. Breitenlechner, C.B.; Friebe, W.; Brunet, E.; Werner, G.; Graul, K.; Thomas, U.; Künkele, K.; Schäfer, W.; Gassel, M.; Bossemeyer, D.; Huber, R.; Engh, R.A.; Masjost, B. Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants. J. Med. Chem., 2005, 48, 163.
34. Donald, A.; McHardy, T.; Rowlands, M.G.; Hunter, L.K.; Davies, T.G.; Berdini, V.; Boyle, R.G.; Aherne, G.W.; Garrett, M.D.; Collins, I. Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design. J. Med. Chem., 2007, 50, 2289.
35. Caldwell, J.J.; Davies, T.G.; Donald, A.; McHardy, T.; Rowlands, M.G.; Aherne, G.W.; Hunter, L.K.; Taylor, K.; Ruddle, R.; Raynaud, F.I.; Verdonk, M.; Workman, P.; Garrett, M.D.; Collins, I. Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration. J. Med. Chem., 2008, 51, 2147.
36. Davies, T.G.; Verdonk, M.L.; Graham, B.; Saalau-Bethell, S.; Hamlett, C.C.F.; McHardy, T.; Collins, I.; Garrett, M.D.; Workman, P.; Woodhead, S.J.; Jhoti, H.; Barford, D. A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera. J. Mol. Biol., 2007, 367, 882.
37. Saxty, G.; Woodhead, S.J.; Berdini, V.; Davies, T.G.; Verdonk, M.L.; Wyatt, P.G.; Boyle, R.G.; Barford, D.; Downham, R.; Garrett, M.D.; Carr, R.A. Identification of inhibitors of protein kinase B using fragment-based lead discovery. J. Med. Chem., 2007, 50, 2293.
38. Lippa, B.; Pan, G.; Corbett, M.; Li, C.; Kauffman, G.S.; Pandit, J.; Robinson, S.; Wei, L.; Kozina, E.; Marr, E.S.; Borzillo, G.; Knauth, E.; Barbacci-Tobin, P.V.; Troutman, M.; Baker, D.Kakar, S.; Clark, T.; Morris, J. Synthesis and structure based optimization of novel Akt inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 3359.
39. Augin, D.; Barthe, P.; Auge-Senegas, M.; Stern, M.; Noguchi, M.; Roumestand, C. Solution structure and backbone dynamics of the pleckstrin homology domain of the human protein kinase B (PKB/Akt). Interaction with inositol phosphates. J. Biomol. NMR, 2004, 28, 137.
40. Harrington, L.S.; Findlay, G.M.; Lamb, R.F. Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem. Sci., 2005, 30, 35.
41. Han, E.K.; Leverson, J.D.; McGonigal, T.; Shah, O.J.; Woods, K.W.; Hunter, T.; Giranda, V.L.; Luo, Y. Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition. Oncogene, 2007, 26, 5655.
42. Cho, H.; Mu, J.; Kim, J.K.; Thorvaldsen, J.L.; Chu, Q.; Crenshaw, E.B.; Kaestner, K.H.; Bartolemei, M.S.; Shulman, G.I.; Birnbaum, M.J. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science, 2001, 292, 1728.
43. George, S.; Rochford, J.J.; Wolfrum, C.; Gray, S.L.; Schinner, S.; Wilson, J.C.; Soos, M.A.; Murgatroyd, P.R.; Williams, R.M.; Acerini, C.L.; Dunger, D.B.; Barford, D.; Umpleby, A.M.; Wareham, N.J.; Davies, H.W.; Schafer, A.J.; Stoffel, M.; O'Rahilly, S.; Barroso, I. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science, 2004, 304, 1325.
44. Walter, K.S.; Deak, M.; Paterson, A.; Hudson, K.; Cohen, P.; Alessi, D.R. Activation of protein kinase B beta and gamma isoforms by insulin in vivo and by 3-phosphoinositide-dependent protein kinase-1 in vitro: comparison with protein kinase B alpha. Biochem. J., 1998, 331, 299.
45. Logie, L.; Ruiz-Alcaraz, A.J.; Keane, M.; Woods, Y.L.; Bain, J.; Marquez, R.; Alessi, D.R.; Sutherland, C. Characterization of a protein kinase B inhibitor in vitro and in insulin-treated liver cells. Diabetes, 2007, 56, 2218.
46. Reuveni, H.; Livnah, N.; Geiger, T.; Klein, S.; Ohne, O.; Cohen, I.; Benhar, M.; Gellerman, G.; Levitzki, A. Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design. Biochemistry, 2002, 4i, 10304.
47. Collins, I.; Caldwell, J.; Fonseca, T.; Donald, A.; Bavetsias, V.; Hunter, L.K.; Garrett, M.D.; Rowlands, M.G.; Aherne, G.W.; Davies, T.G.; Berdini, V.; Woodhead, S.J.; Davis, D.; Seavers, L.C.A.; Wyatt, P.G.; Workman, P.; McDonald, E. Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B. Bioorg. Med. Chem., 2006, 14, 1255.
48. Li, Q.; Li, T.; Zhu, G.; Gong, J.; Claiborne, A.; Dalton, C.; Luo, Y.; Johnson, E.F.; Shi, Y.; Liu, X.; Klinghofer, V.; Bauch, J.L.; Marsh, K.C.; Bouska, J.J.; Arries, S.; De Jong, R.; Oltersdorf, T.; Stoll, V.S.; Jakob, C.G.; Rosenberg, S.H.; Giranda, V.L. Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation. Bioorg. Med. Chem. Lett., 2006, 16, 1679.
49. Li, Q.; Woods, K.W.; Thomas, S.; Zhu, G.; Packard, G.; Fisher, J.; Li, T.; Gong, J.; Dinges, J.; Song, X.; Abrams, J.; Luo, Y.; Johnson, E.F.; Shi, Y.; Liu, X.; Klinghofer, V.; Des Jong, R.; Oltersdorf, T.; Stoll, V.S.; Jakob, C.G.; Rosenberg, S.H.; Giranda, V.L. Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/ Akt) for the treatment of cancer. Bioorg. Med. Chem. Lett., 2006, 16, 2000.
50. Zhu, G.; Gong, J.; Claiborne, A.; Woods, K.W.; Gandhi, V.B.; Thomas, S.; Luo, Y.; Liu, X.; Shi, Y.; Guan, R.; Magnone, S.R.; Klinghofer, V.; Johnson, E.F.; Bouska, J.J.; Shoemaker, A.; Oleksijew, A.; Stoll, V.S.; De Jong, R.; Oltersdorf, T.; Li, Q.; Rosenberg, S.H.; Giranda, V.L. Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity. Bioorg. Med. Chem. Lett., 2006, 16, 3150.
51. Zhu, G.; Gandhi, V.B.; Gong, J.; Luo, Y.; Liu, X.; Shi, Y.; Guan, R.; Magnone, S.R.; Klinghofer, V.; Johnson, E.F.; Bouska, J.J.; Shoemaker, A.; Oleksijew, A.; Jarvis, K.; Park, C.; De Jong, R.; Oltersdorf, T.; Li, Q.; Rosenberg, S.H.; Giranda, V.L. Discovery and SAR of oxindole-pyridine-based protein kinase B/Akt inhibitors for treating cancers. Bioorg. Med. Chem. Lett., 2006, 16, 3424.
52. Thomas, S.A.; Li, T.; Woods, K.W.; Song, X.; Packard, G.; Fischer, J.P.; Diebold, R.B.; Liu, X.; Shi, Y.; Klinghofer, V.; Johnson, E.F.; Bouska, J.J.; Olson, A.; Guan, R.; Magnone, S.R.; Marsh, K.; Luo, Y.; Rosenberg, S.H.; Giranda, V.L.; Li, Q. Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase. Bioorg. Med. Chem. Lett., 2006, 16, 3740.
53. Woods, K.W.; Fischer, J.P.; Claiborne, A.; Li, T.; Thomas, S.A.; Zhu, G.; Diebold, R.B.; Liu, X.; Shi, Y.; Klinghofer, V.; Han, E.K.; Guan, R.; Magnone, S.R.; Johnson, E.F.; Bouska, J.J.; Olson, A.M.; De Jong, R.; Oltersdorf, T.; Luo, Y.; Rosenberg, S.H.; Giranda, V.L.; Li, Q. Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors. Bioorg. Med. Chem., 2006, 14, 6832.
54. Zhu, G.; Gong, J.; Gandhi, V.B.; Woods, K.; Luo, Y.; Liu, X.; Guan, R.; Klinghofer, V.; Johnson, E.F.; Stoll, V.S.; Mamo, M.; Li, Q.; Rosenberg, S.H.; Giranda, V.L. Design and synthesis of pyridine-pyrazolopyridine-based inhibitors of protein kinase B/Akt. Bioorg. Med. Chem., 2007, 15, 2441.
55. Zhu, G.; Gandhi, V.B.; Gong, J.; Thomas, S.; Woods, K.W.; Song, X.; Li, T.; Diebold, R.B.; Luo, Y.; Liu, X.; Guan, R.; Klinghofer, V.; Johnson, E.F.; Bouska, J.; Olson, A.; Marsh, K.C.; Stoll, V.S.; Mamo, M.; Polakowski, J.; Campbell, T.J.; Martin, R.L.; Gintant, G.A.; Penning, T.D.; Li, Q.; Rosenberg, S.H.; Giranda, V.L. Syntheses of potent, selective, and orally bioavailable indazolepyridine series of protein kinase B/Akt inhibitors with reduced hypotension. J. Med. Chem., 2007, 50, 2990.
56. Bamford, M.J.; Alberti, M.J.; Bailey, N.; Davies, S.; Dean, D.K.; Gaiba, A.; Garland, S.; Harling, J.D.; Jung, D.K.; Panchal, T.A.; Parr, C.A.; Steadman, J.G.; Takle, A.K.; Townsend, J.T.; Wilson, D.M.; Witherington, J. (1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: a novel class of potent MSK-1-inhibitors. Bioorg. Med. Chem. Lett., 2005, 15, 3402.
57. Bamford, M.J.; Bailey, N.; Davies, S.; Dean, D.K.; Francis, L.; Panchal, T.A.; Parr, C.A.; Sehmi, S.; Steadman, J.G.; Takle, A.K.; Townsend, J.T.; Wilson, D.M. (1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: further optimisation as highly potent and selective MSK-1-inhibitors. Bioorg. Med. Chem. Lett., 2005, 15, 3407.
58. Stavenger, R.A.; Cui, H.; Dowdell, S.E.; Franz, R.G.; Gaitanopoulos, D.E.; Goodman, K.B.; Hilfiker, M.A.; Ivy, R.L.; Leber, J.D.; Marino Jr., J.P.; Oh, H.; Viet, A.Q.; Xu, W.; Ye, Y.; Zhang, D.; Zhao, Y.; Jolivette, L.J.; Head, M.S.; Semus, S.F.; Elkins, P.A.; Kirkpatrick, R.B.; Dul, E.; Khandekar, S.S.; Yi, T.; Jung, D.K.; Wright, L.L.; Smith, G.K.; Behm, D.J.; Doe, C.P.; Bentley, R.; Chen, Z.X.; Hu, E.; Lee, D. Discovery of aminofurazanazabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity. J. Med. Chem., 2007, 50, 2.
59. Persson, T.; Yde, C.W.; Rasmussen, J.E.; Rasmussen, T.L.; Guerra, B.; Issinger, O.; Nielsen, J. Pyrazole carboxamides and carboxylic acids as protein kinase inhibitors in aberrant eukaryotic signal transduction: induction of growth arrest in MCF-7 cancer cells. Org. Biomol. Chem., 2007, 5, 3877.
60. Laufer, S.A.; Domeyer, D.M.; Scior, T.R.F.; Albrecht, W.; Hauser, D.R.J. Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J. Med. Chem., 2005, 48, 710.
61. Burns, S.; Travers, J.; Collins, I.; Rowlands, M.G.; Newbatt, Y.; Thompson, N.; Garrett, M.D.; Workman, P.; Aherne, W. Identification of small-molecule inhibitors of protein kinase B (PKB/AKT) in an AlphaScreenTM high-throughput screen. J. Biomol. Screen., 2006, 11, 822.
62. Forino, M.; Jung, D.; Easton, J.B.; Houghton, P.J.; Pellechia, M. Virtual docking approaches to protein kinase B inhibition. J. Med. Chem., 2005, 48, 2278.
63. Lin, X.; Murray, J.M.; Rico, A.C.; Wang, M.X.; Chu, D.T.; Zhou, Y.; Del Rosario, M.; Kaufman, S.; Ma, S.; Fang, E.; Crawford, K.; Jefferson, A.B. Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies. Bioorg. Med. Chem. Lett., 2006, 16, 4163.
64. Morgan-Lappe, S.; Woods, K.W.; Li, Q.; Anderson, M.G.; Schudak, M.E.; Luo, Y.; Giranda, V.L.; Fesik, S.W.; Leverson, J.D. RNAi-based screening of the human kinome identifies Aktcooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors. Oncogene, 2006, 25, 1340.
65. Zeng, Z.; Samudio, I.J.; Zhang, W.;Estroz, Z.; Pelicano, H.; Harris, D.; Frolova, O.; Hail, Jr, N.; Chen, W.; Kornblau, S.M.; Huang, P.; Lu, Y.; Mills, G.B.; Andreeff, M.; Konopleva, M. Simultaneous inhibition of PDK1/ AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res., 2006, 66, 3737.
66. Mandal, M.; Kim, S.; Younes, M.N.; Jasser, S.A.; El-Naggar, A.K.; Mills, G.B.; Myers, J.N. The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. Br. J. Cancer, 2005, 92, 1899.
67. Koul, D.; Shen, R.; Bergh, S.; Sheng, X.; Shishodia, S.; Lafortune, T.A.; Lu, Y.; de Groot, J.F.; Mills, G.B.; Yung, W.K.A. Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Mol. Cancer Ther., 2006, 5, 637.
68. Mandal, M.; Younes, M.; Swan, E.A.; Jasser, S.A.; Doan, D.; Yigitbasi, O.; McMurphey, A.; Ludwick, J.; El-Naggar, A.K.; Bucana, C.; Mills, G.B.; Myers, J.N. The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell carcinoma of the head and neck. Oral Oncol., 2006, 42, 430.
69. Zhang, M.; Fang, X.; Liu, H.; Guo. R.; Wu, X.; Li, B.; Zhu, F.; Ling, Y.; Griffith, B.N.; Wang, S.; Yang, D. Bioinformatics-based discovery and characterization of an AKT-selective inhibitor 9-chloro-2-methylellipticinium acetate (CMEP) in breast cancer cells. Cancer Lett., 2007, 252, 244.
70. Jin, X.; Gossett, D.R.; Wang, S.; Yang, D.; Cao, Y.; Chen, J.; Guo, R.; Reynolds, R.K.; Lin, J. Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells. Br. J. Cancer, 2004, 9, 1808.
71. Ko, J.H.; Yeon, S.W.; Ryu, J.S.; Kim, T.; Song, E.; You, H.; Park, R.; Ryu, C. Synthesis and biological evaluation of 5-arylamino-6-chloro-1H-indazole-4,7-diones as inhibitors of protein kinase B/Akt. Bioorg. Med. Chem. Lett., 2006, 16, 6001.
72. Kayser, K.; Glenn, M.P.; Sebti, S.M.; Cheng, J.Q.; Hamilton, A.D. Modifications of the GSK3.. substrate sequence to produce substrate-mimetic inhibitors of Akt as potential anti-cancer therapeutics. Bioorg. Med. Chem. Lett., 2007, 17, 2068.
73. Litman, P.; Ohne, O.; Ben-Yaakov, S.; Shemesh-Darvish, L.; Yechezkel, T.; Salitra, Y.; Rubnov, S.; Cohen, I.; Senderowitz, H.; Kidron, D.; Livnah, O.; Levitzki, A.; Livnah, N. A novel substrate mimetic inhibitor of PKB/Akt inhibits prostate cancer tumor growth in mice by blocking the PKB pathway. Biochemistry, 2007, 46, 4716.
74. Niv, M.; Rubin, H.; Cohen, J.; Tsirunikov, L.; Licht, T.; Peretzman-Shemer, A.; Canán, E.; Tartakovsky, A.; Stein,I.; Albeck, S.; Weinstein, I.; Goldenberg-Furmanov, M.; Tobi, D.; Cohen, E.; Laster, M.; Ben-Sasson, S.; Reuveni, H. Sequence-based design of kinase inhibitors applicable for therapeutics and target identification. J. Biol. Chem., 2004, 279, 1242.
75. Enkvist, E.; Lavogina, D.; Raidaru, G.; Vaasa, A.; Viil, I.; Lust, M.; Viht, K.; Uri, A. Conjugation of adenosine and hexa-(Darginine) leads to a nanomolar bisubstrate-analog inhibitor of basophilic protein kinases. J. Med. Chem., 2006, 49, 7150.
76. Hilgard, P.; Klenner, T.; Stekar, J.; Nosser, G.; Kutscher, B.; Engel, J. D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur. J. Cancer, 1997, 33, 442.
77. Kondapaka, S.B.; Singh, S.S.; Dasmahapatra, G.P.; Sausville, E.A.; Roy, K.K. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol. Cancer Ther., 2003, 2, 1093.
78. Momota, H.; Nerio, E.; Holland, E.C. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res., 2005, 65, 7429.
79. de la Pena, L.; Burgan., W.E.; Carter, D.J.; Hollingshead, M.G.; Satyamitra, M.; Camphausen, K.; Tofilon, P.J. Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells. Mol. Cancer Ther., 2006, 5, 1504.
80. Elrod, H.A.; Lin, Y.; Yue, P.; Wang, X.; Lonial, S.; Khuri, F.R.; Sun, S. The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol. Cancer Ther., 2006, 6, 2029.
81. Papa, V.; Tarrazi, P.L.; Cappellini, A.; Ricci, F.; Billi, A.M.; Evangelisti, C.; Ottaviani, E.; Martinelli, G.; Testoni, N.; McCubrey, J.A.; Martelli, A.M. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia, 2008, 22, 147.
82. Rhamani, M.; Reese, E.; Dai, Y.; Bauer, C.; Payne, S.G.; Dent, P.; Spiegel, S.; Grant, S. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res., 2005, 65, 2422.
83. Ernst, D.S.; Eisenhauer, E.; Wainman, N.; Davis, M.; Lohmann, R.; Baetz, T.; Belanger, K.; Smylie, M. Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest. New Drugs, 2005 23, 569.
84. Posadas, E.M.; Gulley, J.; Arlen, P.M.; Trout, A.; Parnes, H.L.; Wright, J.; Lee, M.J.; Chung, E.J.; Trepel, J.B.; Sparreboom, A.; Chen, C.; Jones, E.; Steinberg, S.M.; Daniels, A.; Figg, W.D.; Dahut, W.L. A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol. Ther., 2005, 4, 1133.
85. Knowling, M.; Blackstein, M.; Tozer, R.; Bramwell, V.; Dancey, J.; Dore, N.; Matthews, S.; Eisenhauer, E. A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial. Invest. New Drugs, 2006, 24, 435.
86. Argiris, A.; Cohen, E.; Karrison, T.; Esparaz, B.; Mauer, A.; Ansari, R.; Wong, S.; Lu, Y.; Pins, M.; Dancey, J.; Vokes, E. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol. Ther., 2006, 5, 766.
87. Marsh Rde, W.; Rocha Lima, C.M.; Levy, D.E.; Mitchell, E.P.; Rowland Jr., K.M.; Benson 3rd, A.B. A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma. Am. J. Clin. Oncol., 2007, 30, 26.
88. Leighl, N.B.; Dent, S.; Clemons, M.; Vandenberg, T.A.; Tozer, R.; Warr, D.G.; Crump, R.M.; Hedley, D.; Pond, G.R.; Dancey, J.E.; Moore, M.J. A Phase 2 study of perifosine in advanced or metastatic breast cancer. Breast Cancer Res. Treat., 2008, 108, 87.
89. Bailey, H.H.; Mahoney, M.R.; Ettinger, D.S.; Maples, W.J.; Fracasso, P.M.; Traynor, A.M.; Erlichman, C.; Okuno, S.H. Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. Cancer, 2006, 107, 2462.
90. Chee, K.G.; Longmate, J.; Quinn, D.I.; Chatta, G.; Pinski. J.; Twardowski, P.; Pan, C.X.; Cambio, A.; Evans, C.P.; Gandara, D.R.; Lara Jr., P.N. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin. Genitourin. Cancer, 2007, 5, 433.
91. Hennessy, B.T.; Lu, Y.; Poradosu, E.; Yu, Q., Yu, S.; Hall, H.; Carey, M.S.; Ravoori, M.; Gonzalez-Angulo, A.M.; Birch, R.; Henderson, I.C.; Kundra, V.; Mills, G.B. Pharmacodynamic markers of perifosine efficacy. Clin. Cancer Res., 2007, 13, 7421.
92. Gills, JJ.; Dennis, P.A. The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt. Expert Opin. Investig. Drugs, 2004, 13, 787.
93. Qiao, L.; Nan, F.; Kunkel, M.; Gallegos, A.; Powis, G.; Kozikowski, A.P. 3-Deoxy-D-myo-inositol 1-phosphate, 1-phosphonate, and ether lipid analogues as inhibitors of phosphatidylinositol-3-kinase signaling and cancer cell growth. J. Med. Chem., 1998, 41, 3303.
94. Hu, Y.; Qiao, L.; Wang, S.; Rong, S.; Meuillet, E.J.; Bergren, M.; Gallegos, A.; Powis, G.; Kozikowski, A.P. 3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth. J. Med. Chem., 2000, 43, 3045.
95. Meuillet, E.J.; Ihle, N.; Baker, A.F.; Gard, J.M.; Stamper, C.; Williams, R.; Coon, A.; Mahadevan, D.; George, B.L.; Kirkpatrick, L.; Powis, G. In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316. Oncol. Res., 2004, 14, 513.
96. Meuillet, E.J.; Mahadevan, D.; Vankayalapati, H.; Berggren, M.; Williams, R.; Coon, A.; Kozikowski, A.P.; Powis, G. Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxyphosphatidyl-myo-inositol analogues. Mol. Cancer Ther., 2003, 2, 389.
97. Kozikowski, A.P.; Sun, H.; Brognard, J.; Dennis, P.A. Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. J. Am. Chem. Soc., 2003, 125, 1144.
98. Castillo, S.S.; Brognard, J.; Petukhov, P.A.; Zhang, C.; Tsurutani, J.; Granville, C.A.; Li, M.; Jung, M.; West, K.A.; Gills, J.G.; Kozikowski, A.P.; Dennis, P.A. Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues. Cancer Res., 2004, 64, 2782.
99. Fujiwara, K.; Iwado, E.; Mills, G.B.; Sawaya, R.; Kondo, S.; Kondo, Y. Akt inhibitor shows anticancer and radiosensitizing effects in malignant glioma cells by inducing autophagy. Intl. J. Oncol., 2007, 31, 753.
100. Maffucci, T.; Piccolo, E.; Cumashi, A.; Iezzi, M.; Riley, A.M.; Saiardi, A.; Godage, H.Y.; Rossi, C.; Broggini, M.; Iacobelli, S.; Potter, B.V.L.; Innocenti, P.; Falasca, M. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects. Cancer Res., 2005, 65, 8339.
101. Mills, S.J.; Komander, D.; Trusselle, M.N.; Safrany, S.T.; van Aalten, D.M.F.; Potter, B.V.L. Novel inositol phospholipid headgroup surrogate crystallized in the pleckstrin homology domain of protein kinase Balpha. Chem. Biol., 2007, 2, 242.
102. Lindsley, C.W.; Zhao, Z.; Leister, W.H.; Robinson, R.G.; Barnett, S.F.; Defeo-Jones, D.; Jones, R.E.; Hartman, G.D.; Huff, J.R.; Huber, H.E.; Duggan, M.E. Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem. Lett., 2005, 15, 761.
103. Barnett, S.F.; Defeo-Jones, D.; Fu, S.; Hanock, P.J.; Haskell, K.M.; Jones, R.E.; Kahana, J.A.; Kral, A.M.; Leander, K.; Lee, L.L.; Malinowski, J.; McAvoy, E.M.; Nahas, D.D.; Robinson, R.G.; Huber, H.E. Identification and characterization of pleckstrin-homologydomain-dependent and isoenzyme-specific Akt inhibitors. Biochem. J., 2005, 385, 399.
104. Lundholt, B.K.; Linde, V.; Loechel, F.; Pedersen, H.; Moller, S.; Praestegaard, M.; Mikkelsen, I.; Scudder, K.; Bjorn, S.P.; Heide, M.; Arkhammar, P.O.G.; Terry, R.; Nielsen, S.J. Identification of Akt pathway inhibitors using redistribution screening on the FLIPR and the IN Cell 3000 analyzer. J. Biomol. Screening, 2005, 10, 20.
105. Ropars, V.; Guichou, J.; Auguin, D.; Barthe, P.; Noguchi, M.; Roumestand, C. Structural basis for Akt (PKB) kinase inhibition by the peptide Akt-in: an NMR study. Compt. Rend. Chimie, 2006, 9, 439.
106. Quintas-Cardama, A.; Kantarjian, H.; Cortes, J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat. Rev. Drug Discov., 2007, 6, 834.
107. Zhao, Z.; Leister, W.H.; Robinson, R.G.; Barnett, S.F.; Defeo-Jones, D.; Jones, R.E.; Hartman, G.D.; Huff, J.R.; Huber, H.E.; Duggan, M.E.; Lindsley, C.W. Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors. Bioorg. Med. Chem. Lett., 2005, 15, 905.
108. Defeo-Jones, D.; Barnett, S.F.; Fu, S.; Hancock, P.J.; Haskell, K.M.; Leander, K.R.; McAvoy, E.; Robinson, R.G.; Duggan, M.E.; Lindsley, C.W.; Zhao, Z.; Huber, H.E.; Jones, R.E. Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol. Cancer Ther., 2005, 4, 271.
109. Hartnett, J.C.; Barnett, S.F.; Bilodeau, M.T.; Defeo-Jones, D.; Hartman, G.D.; Huber, H.E.; Jones, R.E.; Kral, A.M.; Robinson, R.G.; Wu, Z. Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 2194.
110. Zhao, Z.; Robinson, R.G.; Barnett, S.F.; Defeo-Jones, D.; Jones, R.E.; Hartman, G.D.; Huber, H.E.; Duggan, M.E.; Lindsley, C.W. Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity. Bioorg. Med. Chem. Lett., 2008, 18, 49.
111. Wu, Z.; Robinson, R.G.; Fu, S.; Barnett, S.F.; Defeo-Jones, D.; Jones, R.E.; Kral, A.M.; Huber, H.E.; Kohl, N.E.; Hartman, G.D.; Bilodeau, M.T. Rapid assembly of diverse and potent allosteric Akt inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 2211.
112. Siu, T.; Li, Y.; Nagasawa, J.; Liang, J.; Tehrani, L.; Chua, P.; Jones, R.E.; Defeo-Jones, D.; Barnett, S.F.; Robinson, R.G. Discovery of potent and cell-active allosteric dual Akt 1 and 2 inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 4186.
113. Siu, T.; Li, Y.; Nagasawa, J.; Liang, J.; Tehrani, L.; Chua, P.; Jones, R.E.; Defeo-Jones, D.; Barnett, S.F.; Robinson, R.G. The design and synthesis of potent and cell-active allosteric dual Akt 1 and 2 inhibitors devoid of hERG activity. Bioorg. Med. Chem. Lett., 2008, 18, 4191.
114. Toral-Barza, L.; Zhang, W.; Huang, X.; McDonald, L.A.; Salaski, E.; Barbieri, L.R.; Ding, W.; Krishnamurthy, G.; Hu, Y.B.; Lucas, J.; Bernan, V.S.; Cai, P.; Levin, J.I.; Mansour, T.S.; Gibbons, J.J.; Abraham, R.T.; Yu, K. Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT/PKB: mechanistic involvement of AKT catalytic activation loop cysteines. Mol. Cancer Ther., 2007, 6, 3028.
115. Sarker, D.; Workman, P. Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv. Cancer Res., 2007, 96, 213.